Portfolio Lab

Nuvation Bio Inc.

  • Stock
  • Ticker NUVB
  • ISIN US67080N1019
  • NYSE

Health care · Pharmaceuticals · USA

$3.80 −0.26%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Nuvation Bio Inc. since 08/2020, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

NUVBGlobal equities (VT)

$10,000 grew to $4,144. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −93.4% in 10/2023, measured from the peak in 03/2021. The old peak has not been reached again yet.

1-year return
−45.8%
5-year return p.a.
−15.9%
Return p.a. since 08/2020
−14.4%
Volatility p.a.
74.6%
Largest decline
−93.4%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue5.73.14.81342833245
Gross profit1.51.02.39.8––––
Operating income-54-59-64-56-343.9-51-42
EBITDA-54-59-63-56-334.4-51-42
Net income-49-53-59-56-375.4-63-42
Earnings per share0.00-0.16-0.17-0.16-0.110.01-0.18-0.12
Balance sheet
Total assets541492647602595610745778
Liabilities7773274276289291491550
Equity464419373326306320254228
Cash364824899164125259154
Long-term debt––47474747243279
Cash flow
Operating cash flow-46-43-48-53-305.1-43-39
Free cash flow-46-43-48-53-305.1-43-39

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +236.8%, weakest 2022 at −77.4%. 2 of 5 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026−$0.12
6 Aug 2026−$0.18
4 May 2026$0.01
2 Mar 2026−$0.11
3 Nov 2025−$0.16
7 Aug 2025−$0.17
7 May 2025−$0.16
6 Mar 2025$0.00
6 Nov 2024−$0.15
5 Aug 2024−$1.89
14 May 2024−$0.07
29 Feb 2024−$0.07

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.2bn
Market cap in trading currency
$1.34bn
Enterprise value
$964m
P/E
–
P/S
6.65
P/B
5.88
EV/Sales
4.78
EV/EBITDA
–
Earnings yield
–
FCF yield
-7.9%

Results (last four quarters)

Revenue
$202m
Gross profit
–
EBITDA
−$121m
Net income
−$136m
Earnings per share
−$0.40
Revenue per share
$0.57
Revenue growth
+242.6%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-61.2%
Net margin
-67.4%
Return on equity
-49.1%
Return on assets
-17.5%

Balance sheet and cash flow

Cash
$663m
Cash per share
$1.88
Financial debt
$285m
Debt/equity %
125
Current ratio
7.45
Book value per share
$0.65
Operating cash flow
−$106m
Free cash flow
−$106m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
353m
Volume
6.85m
Avg. volume 3 months
5.22m
Relative volume
1.3

Price and technicals

Price
$3.80
1 day
−0.3%
52-week high
$9.54
52-week low
$3.78
Distance to 52-week high
−60.2%
Distance to 52-week low
+0.5%
Distance to 50-day line
−21.9%
Distance to 200-day line
−28.0%
RSI (14)
31
Volatility 1M
58.1%

Performance

1 week
−4.8%
1 month
−19.1%
3 months
−43.8%
6 months
−19.5%
YTD
−57.6%
1 year
−46.9%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has NUVB performed since 08/2020?

$10,000 grew to $3,800 by 20 Nov 2026, which is −14.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is NUVB?

Volatility was 74.6% per year, measured on monthly returns. The largest decline from a peak was −93.4%, with the low in 10/2023.

How does NUVB compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.2% per year at 15.1% volatility, NUVB returned −14.4% at 74.6%. The correlation of monthly returns was 0.33; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Nuvation Bio Inc. (NUVB): Return and risk | Portfolio Lab